US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings Inc.

0.0480

-0.0050-9.43%

Volume:433.24K

Turnover:21.10K

Market Cap:- -

PE:- -

High:0.0578

Open:0.0530

Low:0.0433

Close:0.0530

Loading ...

Overview Company News Filings

BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto

THOMSON REUTERS

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration

Tevogen Bio Enters Agreement to Receive up to $10 Million of Non-Dilutive Grant Funding

THOMSON REUTERS

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

THOMSON REUTERS

BRIEF-Tevogen Bio Broadens Relationship With Microsoft To Deepen Artificial Intelligence Collaboration

Tevogen Bio Broadens Relationship With Microsoft to Deepen Artificial Intelligence Collaboration and Develop Predictcell Technology on Azure

THOMSON REUTERS

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

THOMSON REUTERS

BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

THOMSON REUTERS

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGNW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TVGNW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings Inc.","latestPrice":0.048,"timestamp":1743447902413,"preClose":0.053,"halted":0,"volume":433244,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.005,"latestTime":"03-31 15:20:52 EDT","open":0.053,"high":0.0578,"low":0.0433,"amount":21101.070169592,"amplitude":0.273585,"askPrice":0.058,"askSize":100,"bidPrice":0.0425,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743451200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.053,"volumeRatio":2.200707},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.200707,"shares":0,"dividePrice":0,"high":0.0578,"amplitude":0.273585,"preClose":0.053,"low":0.0433,"week52Low":0.0099,"pbRate":"--","week52High":0.1499,"institutionHeld":0,"latestPrice":0.048,"committee":-0.818182,"eps":0,"divideRate":0,"volume":433244,"delay":0,"ttmEps":0,"open":0.053,"prevYearClose":0.054,"prevWeekClose":0.0579,"prevMonthClose":0.0669,"prevQuarterClose":0.054,"fiveDayClose":0.0638,"twentyDayClose":0.065,"sixtyDayClose":0.054},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGNW\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518208975","title":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208975?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:06","pubTimestamp":1741626362,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTOMarch 10 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO ANNOUNCES UNIQUE T CELL VACCINE UNDER DEVE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2518270844","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2518270671","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270671","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270671?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624800,"startTime":"0","endTime":"0","summary":"Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibilit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-unique-t-164000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2510581991","title":"Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2510581991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510581991?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:30","pubTimestamp":1739226600,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Feb. 10, 2025  -- Tevogen Bio  , is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces pressure to adapt. At the same time, Robert F. Kennedy Jr., who is soon to helm the Department of Health and Human Services, has prioritized affordable healthcare, prompting industry-wide discussions on sustainability and access. Built with these industry themes in mind, Tevogen Bio exemplifies how American biotech can remain competitive and thrive amid growing concerns surrounding affordability, efficiency, and global competition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bios-business-model-addresses-223000195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2507520657","title":"Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2507520657","media":"Insider Monkey","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507520657?lang=en_us&edition=fundamental","pubTime":"2025-01-30 03:33","pubTimestamp":1738179198,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Trending AI Stocks on Latest News. In this article, we are going to take a look at where Tevogen Bio Holdings Inc.  stands against other top trending AI stocks on latest news.The bloodbath that triggered one of the biggest routs in US stock markets appears to be under control. Even as people across China hail the success of their homegrown tech startup DeepSeek, it’s becoming increasingly clear there is room for everyone in the artificial intelligence race. That’s the sentiment echoed across the board as it becomes clear markets might have overreacted on reports China is at the forefront of developing AI models at the lowest costs possible.The reason is simple: our research has shown that we can outperform the market by imitating the top st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-holdings-inc-tvgn-193318272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","MSFT","TVGNW"],"gpt_icon":1},{"id":"2507523074","title":"Tevogen Bio Enters Agreement to Receive up to $10 Million of Non-Dilutive Grant Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2507523074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507523074?lang=en_us&edition=fundamental","pubTime":"2025-01-29 04:49","pubTimestamp":1738097388,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUABVJ0P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0894485498.HKD","LU1720051108.HKD","LU1316542783.SGD","LU1917777945.USD","LU2242650005.HKD","BK4576","LU1366333091.USD","LU1670627923.USD","LU0345768153.USD","LU0109391861.USD","LU0965509010.AUD","BK4532","LU1815336760.USD","LU0203202063.USD","LU1059921491.USD","BK4525","SG9999014575.USD","LU0289941410.SGD","LU0950375773.USD","LU2028103732.USD","LU2458330169.SGD","IE00BMPRXQ63.HKD","LU0426412945.USD","LU2506952097.USD","MSFT","IE0004445015.USD","LU1496350171.SGD","LU0354030511.USD","LU2023251221.USD","LU2286300806.USD","LU1043141123.HKD","IE00B5949003.HKD","LU1037948897.HKD","LU2279689827.SGD","LU0238689110.USD","TVGN","LU2413666426.HKD","TVGNW","LU0792757196.USD","LU0784383803.USD","LU0128525929.USD","LU0868494617.USD","LU1429558221.USD","LU0072461881.USD","IE00BFXG0V08.USD","LU1181866309.USD","LU0162691827.USD","LU2041044095.USD","LU2065169927.USD","LU1334329650.SGD"],"gpt_icon":0},{"id":"2506567589","title":"Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach","url":"https://stock-news.laohu8.com/highlight/detail?id=2506567589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506567589?lang=en_us&edition=fundamental","pubTime":"2025-01-28 03:24","pubTimestamp":1738005873,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nTUA1LZMCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2506113598","title":"BRIEF-Tevogen Bio Broadens Relationship With Microsoft To Deepen Artificial Intelligence Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2506113598","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506113598?lang=en_us&edition=fundamental","pubTime":"2025-01-25 06:46","pubTimestamp":1737758774,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Broadens Relationship With Microsoft To Deepen Artificial Intelligence CollaborationJan 24 (Reuters) - Microsoft Corp MSFT.O:TEVOGEN BIO BROADENS RELATIONSHIP WITH MICROSOFT TO DEEPE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3438f2c5d0af3ac7098ae251e297d7d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nTUA8TJBL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0784384876.USD","LU2764262908.HKD","LU2023250330.USD","LU0057025933.USD","LU0868494617.USD","LU2210149790.SGD","LU0690374961.EUR","LU1642822529.SGD","LU0157215616.USD","LU0310800379.SGD","LU0347712357.USD","LU1868837136.USD","BK4548","LU1691799644.USD","IE00BJTD4N35.SGD","LU2237443382.USD","LU0689626769.HKD","LU0080751232.USD","LU0792757196.USD","LU1244550577.SGD","BK4525","LU1778281490.HKD","LU0426412945.USD","LU0289739343.SGD","LU0095938881.EUR","IE0004445015.USD","LU2361045086.USD","LU2237957811.SGD","LU2592432038.USD","LU2111349929.HKD","LU0889565833.HKD","IE00B4YYXB79.USD","LU2506952097.USD","LU1935042215.USD","LU2362540622.SGD","MSFT","LU1267930573.SGD","LU1934455863.HKD","SG9999002224.SGD","TVGNW","LU0823434583.USD","LU1988902786.USD","LU0187121727.USD","LU2552382215.SGD","SGXZ81514606.USD","LU1868836591.USD","LU1697837992.HKD","LU0353189763.USD","TVGN","LU2065171311.SGD"],"gpt_icon":1},{"id":"2506436819","title":"Tevogen Bio Broadens Relationship With Microsoft to Deepen Artificial Intelligence Collaboration and Develop Predictcell Technology on Azure","url":"https://stock-news.laohu8.com/highlight/detail?id=2506436819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506436819?lang=en_us&edition=fundamental","pubTime":"2025-01-25 06:34","pubTimestamp":1737758066,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3438f2c5d0af3ac7098ae251e297d7d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nTUA8TJBL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289961442.SGD","LU0081259029.USD","LU0882574139.USD","LU0994945656.USD","LU0069063385.USD","LU1323610961.USD","LU2413666426.HKD","LU1037948897.HKD","LU1823568750.SGD","TVGNW","LU0149725797.USD","LU0820562030.AUD","LU1629891620.HKD","IE00BDRTCR15.USD","LU1564329115.USD","LU2756315664.SGD","LU0690374615.EUR","IE00BJTD4V19.USD","IE00BK4W5L77.USD","TVGN","LU1670628061.USD","LU0820561909.HKD","LU1868836914.USD","LU1429558221.USD","LU2361045086.USD","LU1069344957.HKD","LU2357305700.SGD","LU1571399168.USD","LU1582986433.USD","SG9999014575.USD","LU1839511570.USD","LU1066051811.HKD","LU1691799644.USD","IE00BJJMRY28.SGD","IE00BJJMRX11.SGD","LU2242650005.HKD","LU0965509010.AUD","LU1340139317.AUD","LU2552382132.HKD","LU0868494617.USD","IE00B3S45H60.SGD","MSFT","LU0690374961.EUR","LU0511384066.AUD","LU0162691827.USD","IE00B1BXHZ80.USD","LU0894486033.HKD","LU0187121727.USD","IE00B775H168.HKD","IE00BN29S564.USD"],"gpt_icon":0},{"id":"2506819048","title":"Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure","url":"https://stock-news.laohu8.com/highlight/detail?id=2506819048","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506819048?lang=en_us&edition=fundamental","pubTime":"2025-01-25 06:34","pubTimestamp":1737758040,"startTime":"0","endTime":"0","summary":"This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target identification.Tevogen Bio is also proactively investigating potential treatments for Human Papillomavirus .Tevogen.AI, Tevogen Bio’s artificial intelligence effort, will integrate Microsoft’s advanced AI tools and the Microsoft Azure cloud platform into two key objectives:. Rapidly Expanding the ExacTcell Technology Pre-Clinical PipelineBuilding on the successful trial results of TVGN 489, Tevogen Bio aims to utilize machine learning to perform critical simulations that will accelerate the identification of new targets. By leveraging Microsoft’s AI, the company can analyze large datasets across the genome with greater speed and accuracy.By leveraging the Microsoft Azure cloud platform and a suite of advanced AI tools, Tevogen Bio is also proactively investigating potential treatments for Human Pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3438f2c5d0af3ac7098ae251e297d7d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-broadens-relationship-microsoft-223400494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","LU1116320901.HKD","IE00BJLML261.HKD","MSFT","BK4554","LU0965509010.AUD","LU0265550946.USD","LU0683600562.USD","IE00B7KXQ091.USD","IE00BBT3K403.USD","LU2458330169.SGD","LU2756315318.SGD","LU2213496289.HKD","LU2326559502.SGD","SG9999014914.USD","IE0004086264.USD","LU2237438978.USD","LU1732800096.USD","LU1815333072.USD","IE00BKDWB100.SGD","SG9999001424.SGD","LU0175139822.USD","LU2237957902.USD","TVGN","LU0553294199.USD","LU2506951958.HKD","TVGNW","LU0719512351.SGD","IE0004445239.USD","LU0661504455.SGD","IE00BWXC8680.SGD","LU0823421416.USD","LU1670711123.USD","LU0820561909.HKD","LU2087621335.USD","LU1116320737.USD","LU0069063385.USD","LU0267386448.USD","LU2095319765.USD","LU0289739343.SGD","LU2347655156.SGD","BK4503","LU1235295455.SGD","IE00B1BXHZ80.USD","LU1188199696.SGD","LU1551013342.USD","BK4534","LU0689472784.USD","LU1059921491.USD","LU0949170426.SGD","LU1506573853.SGD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2489469783","title":"Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame","url":"https://stock-news.laohu8.com/highlight/detail?id=2489469783","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489469783?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:03","pubTimestamp":1733414580,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Dec. 05, 2024  -- Dr. Ryan Saadi, CEO of Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, Victor Sordillo PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month.Mayor Sordillo was inducted into the Hall of Fame for his dedicated tenure of 24 years of continuous service as a Warren Township Committee Member. As an elected official, Mayor Sordillo served the community by leading the municipal government, providing oversight to the township’s operations, and implementing policies for the public good, essentially working for the benefit of the citizens he represents.Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T ce","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hca4JbhEpE2GIG980_m0Og--~B/aD0xMzE2O3c9ODc3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4ce4244d7a99470b7b5aca6271af6d7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hca4JbhEpE2GIG980_m0Og--~B/aD0xMzE2O3c9ODc3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4ce4244d7a99470b7b5aca6271af6d7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-ryan-saadi-commends-individuals-160300813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2486407771","title":"Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486407771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486407771?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:05","pubTimestamp":1732626300,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 26, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities for key leaders to further expand company capabilities.Tapan V Shah, Head of Investor Relations and Corporate Development, will take on added responsibility for US Government Affairs and Policy.William Keane, Vice President of Strategic Initiatives, will assume additional responsibilities for New Business Development.Wojtek Stobinski, Corporate Identity Lead, will oversee the business integration of any potential future acquisitions.Commitment to C.O.R.E. Values: Curiosity, Optimism, Respect, and Equality. Tevogen Bio’s culture, known as C.O.R.E., underpins the company’s mission and fosters a collaborative environment built on Curiosity, Optimism, Respect, and Equality. These values are more than guiding principles—they are foundational to ho","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-prepares-organizational-readiness-130500359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2485428845","title":"Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428845","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485428845?lang=en_us&edition=fundamental","pubTime":"2024-11-22 04:59","pubTimestamp":1732222783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA1YPKL2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2484390961","title":"BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484390961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484390961?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:52","pubTimestamp":1732053136,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial Nov 19 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS; HIGHLIGHTS SIGNIFICANTLY IMPROVED FI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA4QZXGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2484909633","title":"Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2484909633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484909633?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:50","pubTimestamp":1732053042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA4QZXGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2483337963","title":"Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337963","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337963?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:49","pubTimestamp":1731617340,"startTime":"0","endTime":"0","summary":"Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.In his conversation with the leadership team, Dr. Saadi shared, “Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen’s success would not be possible without its passionate team united by a common vision.” He added, “Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution. Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.”Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-founder-reflects-importance-preserving-204900794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":1}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":32}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGNW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGNW","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGNW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGNW\",market:\"US\",delay:false,,,undefined,":{}}}